RNS Number: 9506 I Agronomics Limited 06 April 2020. The Complete Newsletter is provided here. For text version, please see below:.
The headline should have read' GALY CO. has won a €300,000 prize...' rather than' GALY CO. has won a €300,000 price…'. The full corrected announcement is issued below.. Portfolio Company Update: GALY CO. has won a €300,000 prize at the H&M Global Change Award. The Board of Agronomics is pleased to confirm that GALY CO. has won a €300,000 prize at the H&M Global Change...
Portfolio Company Update: GALY CO. has won a €300,000 price at the H&M Global Change Award. "GALY" has won a €300,000 prize at the H&M Global Change Award for its innovative biotechnology to grow high quality cotton within a laboratory. Five innovations that will transform the fashion industry awarded €1 million by H&M Foundation.
Agronomics 4.9p £17.4m (ANIC.L) Agronomics has completed a Subscription in Seattle Food Tech, Inc., trading as Rebellyous Foods for US$ 99,999.43 for 92,438 Series A Preferred Stock. The Subscription will increase Agronomics existing stake from 1.00% to 1.23% on a fully diluted basis . Since the Company's initial investment, announced on 15 October 2019, Rebellyous has moved to a new 21,000 sq. ft. headquarter facility in West Seattle, WA, USA, allowing for innovative product development and rapid scaling of its production capacity. The team has recent expanding base, selling its plant- based chicken nuggets to schools, cafeterias and hospitals across the USA. Rebellyous is also continuing the development of its optimised production machinery to improve the efficiency of plant-based protein manufacture at scale. #ANIC
The Board of Agronomics is pleased to announce it has today completed a Subscription in Seattle Food Tech, Inc., trading as Rebellyous Foods for US$ 99,999.43 for 92,438 Series A Preferred Stock. Since the Company's initial investment, announced on 15 October 2019, Rebellyous has moved to a new 21,000 sq. ft. headquarter facility in West Seattle, WA, USA, allowing...
Subscription of US$ 2,999,996 in Tropic Biosciences UK Limited. The Board of Agronomics is pleased to announce it has completed a subscription of US$ 2,999,996 for 254,237 Series B Preferred Shares in Tropic Biosciences UK Limited. Tropic Biosciences is an early stage company with costs of approximately £407,833 per month and total assets as at 31 December...
Agronomics #ANIC 5.6p £18.6m Foods United, a major holding, has completed its US$ 200 million financing and rebranded as the LIVEKINDLY co "LIVEKINDLY". LIVEKINDLY is building its portfolio of brands that offer plant-based chicken alternatives, including The Fry Family Food Co and LikeMeat. As a result of this fundraise, the Company's expects its equity interest in LIVEKINDLY co. to be 1.5%.
Portfolio Company Foods United Announces Rebranding as the LIVEKINDLY co., Raises US$ 200 Million to Invest in Plant-Based Chicken Substitutes. The Board at Agronomics is pleased to confirm that Foods United, a major holding, has completed its US$ 200 million financing and rebranded as the LIVEKINDLY co "LIVEKINDLY". New York, NY// MARCH 11, 2020- The LIVEKINDLY co....
Agronomics #ANIC 6.13p £20m $500k subscription by "Simple Agreement for Future Equity" in GALY CO. Equity interest of 4.37%, subject to conversion at a priced equity fundraising round of GALY with a valuation cap of US$10 million. GALY is a Boston, USA, based pioneering biomaterials technology company, producing cotton grown in a lab. The company utilises cell culture to grow cotton cells at faster growth rates than conventional crops, requiring less water, land, gas emissions and no use of harmful chemicals.
Agronomics Limited #ANIC announced that it has completed a subscription of $500,000, in the form of a SAFE in GALY CO. The subscription will give Agronomics an approximate equity interest of 4.37%, subject to conversion at a priced equity fundraising round of GALY with a valuation cap of $10 million. Since the subscription is considered a substantial transaction under AIM Rule 12, this announcement requires certain disclosures under schedule four. GALY is an early stage, pre-revenue company with costs of approximately $20,403 per month and total assets as at 31 December 2019 of approximately $790,000 including cash and near cash of $780,000 and no material liabilities.
Agronomics Announces Investment of US$ 500,000 in GALY CO.. The Board of Agronomics is pleased to announce today it has completed a subscription of US$ 500,000, in the form of a SAFE, in GALY CO.. GALY is a Boston, USA, based pioneering biomaterials technology company, producing cotton grown in a lab.
Agronomics ANIC 6.37p £21.1m BlueNalu, the Company's largest holding, has completed its US$ 20 million Series A financing with participation from major strategic investors with expertise across operations, sales, marketing, distribution and supply chain structuring. Agronomics currently owns 5.9% of BlueNalu, having participated in BlueNalu's seed and series A funding rounds. The book value of BlueNalu is US$ 3.55 million. Richard Reed, Chairman commented on the announcement: "This level of interest from major strategic players in the food industry is unprecedented in the field of cellular agriculture. Combined with the capital inflows to the sector already witnessed in 2020, this is the clearest sign yet that disruption of traditional agriculture from cultivated meat companies is coming sooner than most believe. #ANIC
Agronomics is pleased to announce today that BlueNalu, the Company's largest holding, has completed its US$ 20 million Series A financing with participation from major strategic investors with expertise across operations, sales, marketing, distribution and supply chain structuring. The book value of BlueNalu is US$ 3.55 million.. February 26, 2020- San Diego,...
Agronomics (ANIC.L) 7.625p £25.3m Further subscription of US$ 1m in the form of a SAFE (Simple Agreement For Future Equity) in VitroLabs, Inc. This will be paid using cash from the Company's own resources. The Subscription will increase Agronomics existing potential equity position of 3.79% to 6.15%, subject to converting at the valuation cap of US$ 25m at the time of VitroLab's Series A funding round. Richard Reed, Chairman of Agronomics, provided comments on the investment: - "We continue to be impressed by the strong developments VitroLabs is making as the only company in the world to be using this technology to create real leather, without the requirements of raising animals and the issues surrounding animal welfare, sustainability and efficiency. We are excited for the next 12 months where we expect to see VitroLabs launch their first leather goods to the market." #ANIC
Agronomics Limited #ANIC announced that it has completed a further subscription of $1 million in the form of a SAFE (Simple Agreement for Future Equity, in VitroLabs, Inc ("VitroLabs"). This will be paid using cash from the company's own resources. The Subscription will increase Agronomics existing potential equity position of 3.79% to 6.15%, subject to converting at the valuation cap of $25 million at the time of VitroLab's Series A funding round. The company completed its first subscription of $1.5 million into Vitolabs, the lab-grown leather company based in San Jose, USA, on 17 October 2019.
Agronomics Announces Additional Investment of US$ 1 Million in. The Board of Agronomics is pleased to announce today it has completed a further subscription of US$ 1 million in the form of a SAFE, in VitroLabs, Inc. The Company completed its first subscription of US$ 1.5 million into Vitolabs, the lab-grown leather company based in San Jose, USA, on 17 October 2019.
Agronomics Announces Participation of USD 3 Million in Foods United raise of up to USD 100 Million. The Subscription will give Agronomics an approximate 3% equity interest in Foods United should they raise the full targeted amount of US $100 million.. Foods United is a Delaware Company, with offices located in the US and Switzerland, and is focused on leveraging...
Bid
-
-
-
Ask
  • High
    -
  • OPEN
    -
  • VOL
    -
  • MKT CAP
    -m
  • LOW
    -
  • CLOSE
    -
  • AVG VOL
    -
  • SHARES IN ISSUE
    113.80M

Company Profile

The Company's strategy is to create value for Shareholders through investing in companies that have the potential to generate substantial revenues through the development of biopharmaceutical drugs.

Classification

Market Indices-

Locations

HQ
18 Athol Street
British Isles
Douglas
IM1 1JA
Watchlist